US-based medical technology company BioVentrix has announced the first application of its Revivent-TC System with an endovascular catheter-based approach in a human from within the left ventricle.
The less invasive ventricular enhancement or the LIVE procedure, which is used to reshape and reduce the left ventricle (LV), uses its micro-anchor technology to exclude scar tissue from within the vasculature and without opening the chest.
Go deeper with GlobalData
BioVentrix has reported a successful implant of its Revivent-TC System through the LIVE procedure in a 64-year-old female patient suffering from heart failure symptoms as a result of a myocardial infarction.
The surgery was conducted by Interventional Cardiologist Dr Giedrius Davidavicius and Vilnius University Hospital cardiothoracic surgeon Dr Gintaras Kalinauskas.
Dr Davidavicius said: "This new endovascular delivery system to exclude the scar from within the LV cavity reduces procedural risk, improves accuracy of anchor implant, and enables a more minimally invasive approach for patients suffering from this disease."
The need for a more invasive surgery to implant the Revivent-TC System through the LIVE procedure is replaced by a closed-chest, endovascular approach which involves placing small titanium anchors along the outer surface of the heart and along one of the interior walls.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe anchors are then pulled toward one another, effectively excluding the scarred and non-functioning heart wall. Ventricular volume is immediately reduced as a result of the exclusion, by almost 30-40%.
Image: A model of the human heart. Photo: courtesy of BioVentrix.
